Trombosis venosa profunda: Presente y futuro

Medicina Clinica

Volumn 114, Issue 15, 2000, Pages 584-596

  Botella, Francisco Gabriel ^a   Gómez, Manuel Labiós ^b   Aznar, José Vicente Brasó ^b  

^a NONE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; DEEP VEIN THROMBOSIS; HUMAN; MEDICAL RESEARCH; REVIEW; THROMBOGENESIS;

EID: 0034701472     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71370-4     Document Type: Review

References (142)

1. Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. Arch Intern Med 1997; 157: 1665-1670.
2. Leizorovicz A. Long-term consequences of deep vein thrombosis. Haemostasis 1998; 28 (Supl 3): 1-7.
3. Lundh B, Fagher B. The clinical picture of deep vein thrombosis correlated to the frequency of pulmonary embolism. Acta Med Scand 1981; 210: 353-356.
4. Weinmann EE, Salzman EW. Deep-vein-thrombosis. N Engl J Med 1994; 331: 1630-1641.
5. De Valois JC, Van Shaik CC, Verzijlbergen F, Van Ramshorst B, Eikelboom BC. Contrast venography: from gold standard to «golden backup» in clinically suspected deep vein thrombosis. Eur J Radiol 1990; 11: 131-137.
6. Rosendo A, Fernández D, Lucio R, Latorre J. Epidemiología. En: Güell J, Rosendo A, editores. Enfermedad tromboembólica venosa (ETEV). Síndrome postrombótico. Barcelona: Edika Med, 1995; 1-5.
7. Moody AR, Pollock G, O'connor A, Bagnall M. Lower-limb deep venous thrombosis: direct MR imaging of the thrombus. Radiology 1998; 209: 349-353.
8. Henrot P, Cannard L, Blum A, Roland J. Stratégie diagnostique actuelle de l'embolie pulmonaire. Rev Prat 1998; 48: 124-128.
9. Anand SS, Wells PS, Hunt D, Brill EP, Cook D, Ginsberg IS et al. Does this patient have deep vein thrombosis? JAMA 1998; 279: 1094-1099.
10. Bonal de Falgas J. Comité de profilaxis de la enfermedad tromboembólica. Estudio económico de la ETEV. Incidencia de la TVP y costes de los tratamientos. Boletin del comité de profilaxis de la enfermedad tromboembólica, 1992; 4: 3-25.
11. Ruiz J, Alberich P, Blanquer J, Capelastegui A, Cabezudo MA, De Gregorio MA et al. Normativa de profilaxis de la enfermedad tromboembólica venosa. Arch Bronconeumol 1996; 32: 348-356.
12. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman E, Dalen J. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: S489-S510.
13. Hyers TM, Agnelli G, Hull R, Weg JG, Morris TA, Samama M et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114: S561-S578.
14. Monreal M. La embolia pulmnonar en las puertas del siglo XXI. An Med Interna (Madrid) 1999; 16: 387-388.
15. Lederle FL. Heparin prophylaxis for medical patients? Ann Intern Med 1998; 128: 768-770.
16. Ruiz J, Alberich P, Blanquer J, Capelastegui A, De Gregorio MA, Rodríguez F et al. Normativas SEPAR. Normativa de profilaxis de la enfermedad tromboembólica venosa. Arch Bronconeumol 1996; 32: 1665-1670.
17. Tierney LM, Messina LM. Blood vessels and Treatment. En: Tierney LM, Mcphee SJ, Papadakis MA, editores. Current medical diagnosis and treatment. Stamford, Connecticut: Appleton and Lange, 1999; 473-479.
18. Armon MP, Hopkinson BR. Thrombolysis of acute deep venous thrombosis. Br J Surg 1996; 83: 580-581.
19. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors, a focus on venous thrombosis. Thromb Haemost 1997; 78: 1-6.
20. Layish DT, Dapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest 1997; 111: 218-224.
21. Cohen AT, Edmonson RA, Phillips MJ, Ward VP, Kakkar W. The changing pattern of venous thromboembolic disease. Haemostasis 1996; 26: 65-71.
22. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-1564.
23. Rosenberg RD, Aird WC. Thrombosis. En: Haber E, editor. Molecular cardiovascular medicine. Nueva York: Scientific American, 1995; 115-132.
24. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638-644.
25. Wirchow RLK. Gesammelte Abhandlunggen zur wissenschaftlichen Medizin, Von Meidinger Sohn, Frankfort-am-Main, 1856.
26. Rosendaal FR. Risk factors for venous thrombosis; prevalence, risk, and interaction. Semin Hematol 1997; 34: 171-187.
27. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Evidence that currently available pills are associated with cardiovascular disease: venous disease. En: Hannaford PC, Webb AMC, editores. Evidence-guided prescribing of the pill. Carnforth, UK: Parthenon Publishing, 1996; 61-66.
28. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
29. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis. Oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 82: 1024-1027.
30. Jick II, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
31. Vandenbroucke JP, Helmerhorst F, Rosendaal F. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998; 129: 747.
32. Lensing AWA, Prandoni P, Prins MH, Büller HR. Deep venous thrombosis. Lancet 1999; 353: 479-485.
33. Mannucci PM, Tripodi A, Botasso B, Baudo F, Finazzi G, De Stefano U et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992; 67: 200-202.
34. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
35. Den Heijer M, Blom HJ, Gerrits WBJ, Roseendal FR, Haak HL, Wijermans PW et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-885.
36. Den Heijer M, Koster T, Blom HJ, Bos GM, Briët E, Reitsma P et al. Hyperhomocysteinaemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-762.
37. Selhub J, D'Angelo A. Relationship between homocysteine and thrombotic disease. Am J Med Sci 1998; 316: 129-141.
38. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-2106.
39. Eikelboom J, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375.
40. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate gene risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase. Nature Genet 1995; 10: 111-113.
41. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylene tetrahydrofolate reductase (MTHFR). Thromb Haemost 1997; 78: 523-526.
42. Alhenc-Gelas M, Arnaud E, Nicaud U, Aubry M, Fiessinger J, Aiach M et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 506-510.
43. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina R et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-683.
44. Rice GI, Grant PJ. F VIII coagulant activity and antigen in subjects with ischaemic heart disease. Thromb Haemost 1998; 80: 757-762.
45. Villa P, Aznar J, Vayá A, España F, Ferrando F, Mira Y et al. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb Haemost 1999; 82: 1011-1014.
46. Orbe J, Montes R, Páramo JA. Papel del PAI-1 en los procesos trombóticos. Med Clin (Barc) 1999; 113: 63-69.
47. Martinelli I, Cattaneo M, Panzeri D, Taioli E. Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med 1997; 126: 707-711.
48. Boyer C, Wolf M, Vendrene J, Meyer D. Homozygous variant of antithrombin III: AT III Fontainebleau. Thromb Haemost 1986; 56: 18-22.
49. Okajima K, Ueyama H, Hashimoto Y, Sasaki Y, Matsumoto K, Okabe H et al. Hemozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto. Thromb Haemost 1989; 61: 20-24.
50. 99 Len to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198-202.
51. Martinelli I, Sacchi E, Landi G, Taioli E. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-1797.
52. Price DT, Ridker PM. Factor V Leiden mutation and the risk for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127: 895-903.
53. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr et al. Factor V Leiden (resistance to actived protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-2821.
54. Margaglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannacone L et al. Increased risk for venous thrombosis in carriers of the prothrombin G → 20210 gene variant. Ann Intern Med 1998: 129: 89-93.
55. Reuner KH, Ruf A, Grau A, Rickmann H, Stolz E, Juttler E et al. Prothrombin gene G 20210 → A transition is a risk factor for cerebral venous thrombosis. Stroke 1998; 29: 1765-1769.
56. De Stefano V, Chinsolo P, Paciarioni K, Castorelli I, Rossi E, Molinari M et al. Prothrombin G 20210 A mutant genotype is a risk factor for cerebrovascular disease in young patients. Blood 1998; 91: 3562-3565.
57. Arruda VR, Siquiera LH, Chiaparini LC, Coelho OR; Mansur AP, Ramires A et al. Prevalence of the prothrombin gene variant 20210 → A among patients with myocardial infarction. Cardiovasc Resp 1998; 37: 42-45.
58. Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS et al. Hepatic outflow obstruction (Budd-Chiari syndrome): experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994; 73: 21-36.
59. Hillman P, Lewis SM, Bessler M, Luzzato L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-1258.
60. Socie G, Mari JY, De Gramont A, Rio B, Leporrier M, Rosec et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996; 348: 573-577.
61. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
62. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzuconi MG, Schinco PC et al. Natural history and risk factors for thrombosis in 360 patiens with antiphospholipid antibodies: a four-year prospective study form the Italian Registry. Am J Med 1996; 100: 530-536.
63. Comp PC, Elrod JP, Karzneski S. Warfarin-induced skin necrosis. Semin Thromb Haemost 1990; 16: 293-298.
64. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine (Baltimore) 1981; 60: 413-428.
65. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VII related antigen. Thromb Res 1985; 38: 469-479.
66. Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56: 191-207.
67. Prandoni P, Lensing AW, Congo A, Cuppini S, Villalta S, Carta M et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
68. Halstuk KS, Mahler D, Baker WH. late sequelae of deep venous thrombosis. Diagnostic and therapeutic considerations. Am J Surg 1984; 147: 216-220.
69. Saarinen J. Late sequelae of acute deep venous thrombosis: Evaluation five and ten years after. Phlebology 1995; 10: 106-109.
70. Hobson J. Venous insufficiency at work. Angiology 1997; 48: 577-582.
71. Biguzzi E, Mozzi E, Alatri A, Taioli E, Moia M, Mannucci P. The posttrombotic syndrome in young women: Retrospective Evaluation of Prognostic Factors. Thromb Haemost 1998; 80: 575-577.
72. Khan SR, Josep L, Abenhaim L, Leclerc JR. Clinical prediction of deep vein thrombosis in patients with leg symptoms. Thromb Haemost 1999; 81: 353-357.
73. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L et al. Application of a diagnostic clinical model for the management of hospitalizaded patients with suspected deep-vein thrombosis. Thromb Haemost 1999; 81: 353-357.
74. Jansen MCH, Heebels AE, De Metz M, Verbruggen H, Wollersheim H, Jansen S et al. Reliability of five rapid D-Dimer assays compared to ELISA in the exclusion of deep vein thrombosis. Thromb Haemost 1997; 77: 262-266.
75. Elias A, Aptel I, Huc B, Chale JJ, Nguyen F, Cambus JP et al. D-Dimer test and diagnosis of deep vein thrombosis: a comparative study of 7 assays. Thromb Haemost 1996; 76: 518-522.
76. Janssen MC, Verbruggen H, Wollersheim H, Hoogkamer B, Van Lagen H, Nóváková IR. D-Dimer determination to assess regression of deep venous thrombosis. Thromb Haemost 1997; 78: 799-802.
77. Ginsberg JS, Kearon C, Douketis J, Turpie AG, Brills EP, Stevens P et al. D-Dimer testing and impedance plethysmography were effective for exclusion of deep venous thrombosis. Arch Intern Med 1997; 157: 1077-1081.
78. Bounameaux H, Perrier A. Rapid diagnosis of deep vein thrombosis in symptomatic patients: a comparison between four different diagnostic strategies. Thhromb Haemost 1999; 82: 1360-1361.
79. Fraser JD, Anderson DR. Deep venous thrombosis: Recent advances and optimal investigation with US. Radiology 1999; 211: 9-24.
80. Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998; 129: 1044-1049.
81. Prandoni P, Cogo A, Bernardi E, Villalta S, Polistena P, Simioni P et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993; 88: 1730-1735.
82. Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998; 128: 663-677.
83. Heijboer H, Jonbloets LM, Buller HR, Lensing AW, ten Cate JW. Clinical utility of real-time compression ultrasonography for diagnostic management of patients with recurrent venous thrombosis. Acta Radiol 1992; 33: 297-300.
84. Pilcher DB, Ricci MA. Vascular ultrasound. Surg Clin North Am 1998; 78: 273-293.
85. Catalano C, Pavone P, Laghi A, Scipioni A, Fanelli F, Assael FG et al. Role fo MR venography in the evaluation of deep venous thrombosis. Acta Radiol 1997; 38: 907-912.
86. Sostman HD, Layish DT, Tapson VF, Spritzer CE, Delong DM, Trotter P et al. Prospective comparison of helical CT and RM imaging in patients with clinically suspected pulmonary embolism. J Mag Reson Imaging 1996; 6: 275-281.
87. Carpenter resonance venography detection of deep venous thrombolisis. Comparison with contrast venography and duplex. Doppler ultrasonography. J Vasc Surg 1993; 18: 734-741.
88. Spritzer CE, Trotter P, Sostman HD. Deep venous thrombosis: gradient-recalled-echo MR imaging changes over time-experience in 10 patients. Radiology 1998; 208: 631-639.
89. Dorfman GS, Cronan JJ. Asymptomatic pulmonary embolism in deep venous thrombosis: long-term follow-up. Radiology 1987; 165: 205-211.
90. Hyers T, Agnelli G, Hull R, Weg J, Morris T, Samama S et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 8: S561-S578.
91. Gould M, Dembitser A, Doyle R, Hastie T, Garber AM. Low-Molecular-weights heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-Analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-809.
92. Aguilar D, Goldhaber δ. Clinical uses of low-molecular weight. Chest 1999; 115: 1418-1423.
93. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot bound thrombus is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391.
94. Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Hematol 1999; 36: 17-21.
95. Weitz JI, Hirsh J. New antithrombotic agents. Chest 1998; 144: S71 5-S727.
96. Farred J, Callas D, Hoppensteadt D, Lewis B, Bick R, Walenga J. Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol 1999; 36 (Supl 1): 42-56.
97. Hursting MJ, Alford KL, Becker JP. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23: 503-516.
98. Kitchen S, Lampietro R, Woolley A, Preston F. Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82: 1289-1293.
99. Faria F, Kelen E, Sampaio C, Bon C, Duval N, Chudzinski-Tavassi A. A new factor Xa inhibitor (lefaxin) from the Haementeria depressa Leech. Thromb Haemost 1999; 82: 1469-1473.
100. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism Chest 1999; 115: 1695-1707.
101. Weidmann B, Jansen W, Franzen B, Tauchert M. Fibrinolytic therapy of deep vein thrombosis. Med Klin 1999; 94: 140-149.
102. Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: follow-up results of a prospective trial. Acta Med Scand 1982; 211: 65.68.
103. Goldhaber SZ, Kessler CM, Heit J, Morkis J, Sharma GV, Dawley D et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism Lancet 1988; 2: 293-298.
104. Horne MC. Thrombolytic therapy for deep venous thrombosis? JAMA 1999; 282: 2164-2166.
105. Mayor GE, Galloway JM. Iliofemoral venous thrombosis: pathological considerations. Br J Surg 1969; 56: 45-59.
106. Lansing AM, Davis WM. Five-year-follow-up study of iliofemoral venous thrombectomy. Ann Surg 1968; 620-628.
107. Comerota AJ. Venous thrombectomy and arteriovenous fistula versus anticoagulation in the treatment of iliofemoral venous thrombosis. J Vasc Surg 19923; 15: 887-889.
108. Mahorner H, Castleberry JW, Coleman WO. Attempts to restore function in major veins which are the site of massive thrombosis. Ann Surg 1957; 146: 510-522.
109. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girad P et al. A clinical trial of vena cava filters in the prevention of pulmonary embolsim in patients with proximal deep vein thrombosis. N Engl J Med 1998; 338: 409-415.
110. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122-140.
111. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic rante. Chest 1998; 114: S445-S469.
112. Greer IA. The special case of venous thromboembolism in pregnancy. Haemostasis 1998: 28 (Supl): 22-34.
113. Dunn AS, Coller B. Outpatient treatment of deep vein thrombosis: Translating clinical trials into practice. Am J Med 1999; 106: 660-669.
114. Van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Buller HR: Replacing inpatient care by outpatient care in treatment of deep venous thrombosis-an economic evaluation. Tasman study group. Thromb Haemost 1998; 79: 259-263.
115. Koopman M, Prandoni P, Piovella F, Ocklefort PA, Brandjes DPM, Van der Meer J et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in three hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687.
116. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J. A comparison of low-molecular-weight heparin administered primarialy at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681.
117. Columbus Investigators. Low-Molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662.
118. Yusen RD, Haraden BM, Gage BF, Woodward RS, Rubin BG, Botney MD. Criteria for outpatient management of proximal lower extremity deep venous thrombosis Chest 1999; 115: 972-979.
119. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish venous thrombosis dalteparin trial group. J Intern Med 1996; 240: 395-401.
120. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998; 158: 2001-2003.
121. Wells PS, Kovacs MJ, Bormanis J, Forgie M, Goudie D, Morrow B et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin. Arch Intern Med 1998; 158: 1809-1812.
122. Gran E, Real E, Pastor E, Viciano V, Aguiló J. Home treatment of deep vein thrombosis: a two years experience at a single institution. Haematologica 1998; 83: 438-441.
123. Ting SBN, Ziegenbein RW, Gan TE, Catalano JV, Monagle P, Silvers J et al. Dalteparin for deep venous thrombosis: a hospital-in-the-home program. Med J Australia 1998; 168: 272-276.
124. Monreal M, López E, Ruiz J, Callejas JM, Arias A. Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: a prospective study. Eur J Vasc Surg 1994; 81: 996-997.
125. Monreal M, Urrutia A, Marti S, Cuxart A, Roncales J. Platelet count and the risk of bleeding in hospitalized patients with venous thromboembolism starting anticoagulant therapy. Haemostasis 1997; 27: 91-98.
126. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327.
127. Landefeld CS, Goldman L. Maior bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
128. Fihn SD, Callahan CM, Martin D, Mcdonell MB, Henikoff JG, White RH et al. The risk for severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124: 970-979.
129. Dalen JE, Hirsh J. ACCP-HLBI National conference of antithrombotic therapy. Chest 1986; 89 (Supl): 1-106.
130. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
131. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars SG, Nicol P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
132. Schulman S. Optimal duration of oral anticoagulant therapy in venous thromboembolism. Thromb Haemost 1997; 78: 693-698.
133. Schafer AI. Venous thrombosis as a chronic disease. N Engl J Med 1999; 340: 955-956.
134. Schulman S, Granqvist S, Homström M, Carlsson A, Lindmarker P, Nicole P et al. The duration of oral anticoagulant therapy after a second episode of venous tromboembolism. N Engl J Med 1997; 336: 393-398.
135. Kearon C, Gent M, Hirsh J, Weitz J, Kovaks M, Anderson D et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
136. Brown MM, Sevan D. Is inherited thrombophilia a risk facton for arterial stroke? J Neurol Neurosurg Psychiatry 1998; 65: 617.
137. Rodeghiero F, Tosetto A. Activated protein C resistente and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-650.
138. Schafer AI, editor. Molecular mechanisms of hypercoagulable states. Austin, Tex: Landes Bioscience, 1997; 212-249.
139. Kierkegaard A. Incidence of acute deep vein thrombosis in two districts. A phlebographic study. Acta Chir Scand 1980; 146: 267-269.
140. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DV, Patwardhan NA, Jovanovic B. Population-based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-938.
141. Salzman EW, Hirsch J. The epidemiology, pathogenesis and natural history of venous thrombosis. En: Colman RW, Hirsch J, Marder VJ, Salzman EW, editores. Hemostasis and thrombosis. Basic principles and clinical practice. Filadelfia: JB Lippincott, 1993; 1346-1366.
142. Bertina RM, Rosendaal FR. Venous thrombosis in the interaction of genes and environment. N Engl J Med 1998; 338: 1840-1841.